Your browser doesn't support javascript.
loading
Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk.
Gao, Rui; Liao, Xin; Huang, Wanrong; Zeng, Rujun; Qin, Lang; Bai, Peng.
Afiliação
  • Gao R; The Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Liao X; Key Laboratory of Birth Defects and Related Diseases of Women and Children of the Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Huang W; West China School of Medicine, Sichuan University, Chengdu, China.
  • Zeng R; Key Laboratory of Birth Defects and Related Diseases of Women and Children of the Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Qin L; Department of the Central Operating Unit, West China Second University Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China.
  • Bai P; Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
Front Endocrinol (Lausanne) ; 13: 905263, 2022.
Article em En | MEDLINE | ID: mdl-35757417
ABSTRACT

Purpose:

To explore another choice for a controlled ovarian stimulation (COS) protocol that does not increase severe ovarian hyperstimulation syndrome (OHSS) risk among polycystic ovarian syndrome (PCOS) patients with specific clinical features.

Methods:

A retrospective study was performed. Two hundred and fifty-nine participants were divided into two groups, group 1 (fixed GnRH antagonist protocol, n = 295) and group 2 (follicular-phase GnRH agonist protocol, n = 69) according to COS protocols. The basic characteristics and laboratory indicators between these two groups were compared. The severe OHSS rate and clinical pregnancy rate were selected as indicators to evaluate the risks and benefits of the two COS protocols. Subgroup analyses for the severe OHSS rate and clinical pregnancy rate were performed based on baseline luteinizing hormone/follicle-stimulating hormone (bLH/FSH) and anti-Mullerian hormone (AMH) levels.

Results:

The severe OHSS rate was statistically higher in group 2 than in group 1 (11.6% vs. 3.7%, p = 0.008), but the biochemical pregnancy rate and clinical pregnancy rate showed no statistical difference between the groups (71.9% vs. 60.3% and 62.5% vs. 54.3%). In the higher bLH/FSH subgroup (≥1.33) and the higher serum AMH level subgroup (>3.4 ng/ml), severe OHSS incidence was statistically higher in group 2 compared to group 1, but this incidence was lower in the bLH/FSH subgroup (<1.33) and the subgroup with lower serum AMH levels (≤3.4 ng/ml); a difference in severe OHSS risk was not observed. There was no statistical difference between the two groups regarding clinical pregnancy rate in any subgroup.

Conclusion:

The limited evidence from this study indicates that in PCOS patients with lower bLH/FSH levels (<1.33) and lower serum AMH levels (≤3.4 ng/ml), a follicular-phase GnRH agonist protocol may be another choice that does not increase the risk of severe OHSS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Síndrome do Ovário Policístico / Síndrome de Hiperestimulação Ovariana Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Síndrome do Ovário Policístico / Síndrome de Hiperestimulação Ovariana Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China